Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05752149
Other study ID # NL74742.078.21
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date November 2025

Study information

Verified date February 2024
Source Erasmus Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.


Description:

This is a two staged clinical trial to investigate intraoperative fluorescence imaging in patientsundergoing TLE. WP-I is a dose finding study in which 2 doses will be tested with a possibility of a third dosing group. Every dosing cohort comprises 3 patients. After WP-I, an interim analysis will be performed to decide the optimal dose. The optimal dose will be based on the TBR and the performance in detecting the most close margin (i.e. 'the sentinel margin'). A TBR of at least 1.5 is required for the optimal dose. If a positive margin is missed with fluorescence imaging, the concerned dose will be defined as suboptimal. WP-II is an extension cohort of the optimal dose cohort selected in WP-I. WP-II will comprise of 18 patients. The endpoints for WP-II are: - the rate of tumor free resection margins based on the current golden standard; - Sensitivity, specificity and positive predictive value of FLI; - The intraoperative change in surgical management based on FLI; - FLI of excised cervical lymph nodes; - Influence of previous radiotherapy on the FLI performance; - Adverse events and toxicity after intravenous injection with cRGD-ZW800-1;


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 27
Est. completion date November 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with biopsy-proven squamous cell Laryngeal and hypopharyngeal cancer, eligible for surgical resection of the tumor by TLE; - = 18 years of age; - Written informed consent must be obtained; - Sufficient knowledge of the Dutch language to understand the informed consent form; Exclusion Criteria: - History of a clinically significant allergy or anaphylactic reactions to any of the components of the agent; - Other synchronous biopsy proven malignancies currently active, except for adequately treated in situ carcinoma of cervix and basal, squamous cell skin carcinoma, or other head- and neck squamous cell cancer; - Patients pregnant or breastfeeding; - Patients with renal insufficiency (defined as eGFR < 60); - Patients with previous kidney transplantation or a solitary functioning kidney; - Patients using medications that may significantly impair renal function (i.e. NSAIDs, particularly COX-2 inhibitors), that cannot be paused during the course of the study; - Patients with ASA classification of 4 or higher; - Patients with measured QTc of 500 ms or higher at screening; - Patients with laboratory abnormalities defined as: - Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the ULN or; - Total bilirubin above 3 times the ULN or; - Platelet count below 100 x 109/L or; - Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males). - Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired or weakened immune system, caused by either a preexisting disease or concomitant medications;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CRGD-ZW800-1
Intravenous administration of study drug at lesat 2h prior to surgery

Locations

Country Name City State
Netherlands Erasmus Medical Center Rotterdam Zuid-Holland

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary WP-I: the optimal dose of cRGD-ZW800-1 for FLI of laryngeal and hypopharyngeal cancer Based on the tumor-to-background ratio (TBR) on breadloaves. Higher TBRs indicate a better outcome Up to 48 hours after administration (Depending on pathology grossing)
Primary WP-II: the rate of clear tumor resection margins Through histopathology, up to max 4 weeks post-op
See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Not yet recruiting NCT06137378 - European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] Phase 2
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Withdrawn NCT04831450 - Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03114462 - Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer Phase 1
Terminated NCT02464137 - HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer Phase 1

External Links